RR

Rajat Ranga

Active Director Director DIN 11105025
DIN 11105025 First appointment Apr 2025 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2025
Shareholding value •••• Premium profile

About Rajat Ranga

Data last updated:

Rajat Ranga is a Director at Viovas Pharma Private Limited (since 2025). The company operates in Pharma. Viovas Pharma Private Limited reported revenue of ₹1.27 Cr (FY 2025).

DIN 11105025
Primary Designation Director
Industry Pharma
First Appointment 28 Apr 2025
Oldest Company Age 3 yrs
Largest company Viovas Pharma Private Limited · ₹1.27 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Viovas Pharma Private Limited U47721DL2023PTC417099
Director28 Apr 20252023₹1.27 Cr (FY 2025)Active

Board colleagues of Rajat Ranga

Directorship timeline

Open interactive timeline →
Viovas Pharma Private Limited
Premium access

Shareholding and investment profile for Rajat Ranga

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rajat Ranga

Rajat Ranga currently holds 1 directorship: Viovas Pharma Private Limited (Director, since 28 Apr 2025, revenue ₹1.27 Cr (FY 2025)).

Rajat Ranga was first appointed on 28 Apr 2025 as Director at Viovas Pharma Private Limited.

The current boards of Rajat Ranga's companies include Nasreen Shabbir Ahmed (Viovas Pharma Private Limited), Ruby Chaudhary (Viovas Pharma Private Limited), Vijay Pal Solanki (Viovas Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available